Long-term Impacts of 1alpha-Hydroxy Vitamin D3 on The Bone Mineral Density and Bone Metabolism during Percutaneous Estrogen Replacement Therapy in Postmenopausal Women

Kim, S W; Park, E D; Kim, D H; Kim, H Y; Suk, W I; Seo, N W; Lee, S M; Noh, S H

Abstract

To evaluate the impacts of vitamin-D on the bone mineral density and bone metabolism in the estrogen replacement 1-year trials of 3 grops: Group 1 was 35 wemen recieved the treatment with 0.5 microgram of vitamin D daily by oral administration, Group II was 50 wemen recieved the treatment with 50 microgram of 17 beta-estradiol by percutaneous administration, Group III was 35 wemen recieved with percutaneous estrogen with daily addition of vitamin D. In all subjects, bone mineral density (BMD) of lumbar spine and femur neck, urinary calcium/creatinine ratio, and serum osteocalcin were measured before treatment and after 6 and 12 months of treatment. BMD of femur neck in Group I, Group II and Group III increased but not significantly compared to basal level at 6 months and/or 12 months of treatment. As for BMD of lumbar spine, it increased significantly during the treatment in Group II and Group III, but not in Group I . Serum osteocalcin in Group II and Group III decreased significanly at 12 months of treatment compared with Group I . Urinary calcium/creatinine ratio in Group II, Group III, decreased significantly at 12 months of treatment compared with Group I. From the above results, it might be suggested that combined therapy (percutaneous estrogen with daily addition of vitamin D) is more effective in post menopausal women with the protection on decreasing bone mineral density.